|
||
Nitromak Retard Pregnancy |
||
Nitromak Retard crosses the placenta (David 2000).
Following a single maternal IV bolus dose of Nitromak Retard at the time of incision prior to cesarean delivery, concentrations in the umbilical cord at birth were significantly lower than the maternal plasma (~1 minute after dosing); a wide variation in maternal plasma concentrations was observed (David 2000). Following application of a transdermal patch 0.4 mg/hour to pregnant women 20 to 36 weeks gestation, concentrations of Nitromak Retard were low but detectable in the fetal serum ~1 to 4 hours after the patch was applied (fetal/maternal ratio: 0.23) (Bustard 2003).
Intravenous Nitromak Retard is recommended in pregnant females when preeclampsia is associated with pulmonary edema (ESC [Regitz-Zagrosek 2018]). Nitromak Retard may be beneficial in cases of uterine inversion following delivery when immediate relaxation of the uterus is needed (ACOG 183 2017). Additional data may be necessary to further define the role of Nitromak Retard use in other conditions requiring uterine relaxation, such as external cephalic version, retained placenta, or preterm labor (Abdel-Aleem 2015; Axemo 1998; Caponas 2001; Cluver 2015; Duckitt 2014).
AU: Contraindicated UK: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. US: Caution is recommended. Excreted into human milk: Unknown Excreted into animal milk: Data not available
Topical use for anal fissures by nursing mothers appears to have no adverse effects on their breastfed infants. This drug has been used topically on the nipples for Raynaud phenomenon of the nipples, but only after discontinuation of breastfeeding.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|